Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research report sent to investors on Monday morning. The firm issued a hold rating on the stock.

OGEN opened at $0.36 on Monday. The firm has a market capitalization of $42.25 million, a PE ratio of -2.59 and a beta of 0.09. The company has a fifty day moving average of $0.41. Oragenics has a 12-month low of $0.30 and a 12-month high of $1.15.

Oragenics Company Profile (Get Rating)

Oragenics, Inc is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus.

Featured Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.